Immuneering (NASDAQ:IMRX) Upgraded by Chardan Capital to “Strong-Buy” Rating

Chardan Capital upgraded shares of Immuneering (NASDAQ:IMRX) to a strong-buy rating in a report issued on Monday morning,Zacks.com reports.

A number of other equities research analysts have also recently commented on the company. Cantor Fitzgerald assumed coverage on Immuneering in a research note on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price target for the company. Needham & Company LLC upped their price target on shares of Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Wednesday, June 24th. Oppenheimer reissued an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Finally, Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $18.00.

Immuneering Trading Down 0.2%

Shares of IMRX stock opened at $4.39 on Monday. Immuneering has a 12-month low of $2.90 and a 12-month high of $10.08. The business’s fifty day simple moving average is $4.60 and its 200-day simple moving average is $4.98. The company has a market cap of $284.03 million, a PE ratio of -3.75 and a beta of 0.43.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). The firm had revenue of $0.36 million during the quarter. On average, equities analysts forecast that Immuneering will post -1.09 earnings per share for the current year.

Hedge Funds Weigh In On Immuneering

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in Immuneering during the 1st quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new position in Immuneering during the fourth quarter valued at $33,000. Levin Capital Strategies L.P. purchased a new stake in Immuneering in the first quarter valued at $53,000. Focus Financial Network Inc. purchased a new stake in Immuneering in the second quarter valued at $62,000. Finally, Cetera Investment Advisers acquired a new stake in Immuneering during the 1st quarter worth about $67,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

More Immuneering News

Here are the key news stories impacting Immuneering this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” rating and a $14 price target, implying substantial upside from the reference price of $4.39. HC Wainwright starts Immuneering at Buy
• Positive Sentiment: Chardan Capital upgraded Immuneering to “Strong Buy,” adding to the favorable analyst sentiment around IMRX.
• Positive Sentiment: Immuneering reported a 17.3-month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy. The company said 84% of evaluable patients were weight-stable or gained weight after three months, supporting the drug’s potential efficacy and tolerability. Immuneering second-quarter financial results and business updates
• Positive Sentiment: The pivotal Phase 3 MAPKeeper 301 trial is enrolling and dosing patients across more than 30 locations. Management expects the company’s $182.7 million cash position to fund operations into 2029, reducing near-term financing pressure.
• Positive Sentiment: A peer-reviewed Cancer Research publication highlighted atebimetinib’s broad preclinical activity against RAS- and RAF-mutant tumors and potential for favorable tolerability.
• Neutral Sentiment: Upcoming catalysts include an expected Phase 2 atebimetinib and anti-PD-1 lung cancer study initiation in the second half of 2026, additional preclinical data in the fourth quarter, and MAPKeeper 301 topline results targeted for mid-2028.
• Negative Sentiment: Second-quarter adjusted results were slightly weaker than expected: Immuneering reported a $0.27 per-share loss versus the $0.26 consensus loss, while revenue was only $0.36 million.
• Negative Sentiment: The quarterly net loss widened to $17.3 million from $14.4 million a year earlier, with research and development costs rising to $14.0 million as clinical spending increased. IMRX remains unprofitable and has not yet completed a registrational trial.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.